Avid Bioservices Inc expected to post a loss of 6 cents a share - Earnings Preview

Avid Bioservices

08/03/2024 11:11

* Avid Bioservices Inc  CDMO.OQ   CDMO.O  is expected
to show a
fall in quarterly revenue when it reports  results on March 8
(estimated) for the period ending January 31 2024
    * The Tustin California-based  company is expected to report
a
11.6% decrease in revenue to $33.594 million from $38.02 million
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Avid Bioservices Inc is
for a
loss of 6 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Avid
Bioservices
Inc is $14.50​, above​ its last closing price of $6.10. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Oct. 31 2023  -0.06       -0.06      -0.15     Missed  -140
 Jul. 31 2023  -0.03       -0.03      -0.03     Met     -9.1
 Apr. 30 2023  0.00        0.00       0.00      Met     ​
 Jan. 31 2023  -0.04       -0.03      0.01      Beat    128.6
 ​​Oct.        0.00        0.00       -0.02     Missed  -300
 31 2022                                                
 Jul. 31 2022  0.04        0.04       0.02      Missed  -45.5​
 Apr. 30 2022  0.01        0.01       0.01      Met     0
 Jan. 31 2022  0.05        0.04       0.04      Met     0
 This summary was machine generated March 8 at 11:11 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)